The Long Non-Coding RNA ANRIL in Cancers

Sanchez, Aymeric; Lhuillier, Julien; Grosjean, Guillaume; Ayadi, Lilia; Maenner, Sylvain

doi:10.3390/cancers15164160

Cited by 6 publications

(4 citation statements)

References 275 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ANRIL (antisense noncoding RNA in INK4 locus) is considered an oncogenic lncRNA linked to GBM. The dysregulation of ANRIL in blood has been associated with cancers in general, cardiovascular diseases [247], and type 2 diabetes mellitus [248] (see Table 2). This lncRNA can modulate gene expression at the post-transcriptional level by interacting with miRNAs and proteins [249].…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

“…ANRIL functions as a scaffold for PRC2 and, therefore, participates in epigenetic gene silencing [250] and is involved in alternative splicing in HEK293 and HUVEC cells [251]. Through these mechanisms, ANRIL contributes to tumourigenesis processes, increasing cell proliferation, migration, invasion, and metastasis and suppressing apoptosis and senescence [248]. Upregulated ANRIL expression levels have been found to be linked with cancers such as lung, stomach, breast, ovarian, cervical, colorectal, bladder, thyroid, brain, osteosarcoma, myeloma, prostate, endometrial, renal, leukaemia, melanoma, retinoblastoma, and hepatocellular carcinoma [248].…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

“…Through these mechanisms, ANRIL contributes to tumourigenesis processes, increasing cell proliferation, migration, invasion, and metastasis and suppressing apoptosis and senescence [248]. Upregulated ANRIL expression levels have been found to be linked with cancers such as lung, stomach, breast, ovarian, cervical, colorectal, bladder, thyroid, brain, osteosarcoma, myeloma, prostate, endometrial, renal, leukaemia, melanoma, retinoblastoma, and hepatocellular carcinoma [248]. In addition to an increased risk of cancer, polymorphisms in the ANRIL gene are also associated with the risk of atherosclerosis, obesity, and type 2 diabetes.…”

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

See 2 more Smart Citations

lncRNA Biomarkers of Glioblastoma Multiforme

Pokorná,

Černá,

Boussios

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are RNA molecules of 200 nucleotides or more in length that are not translated into proteins. Their expression is tissue-specific, with the vast majority involved in the regulation of cellular processes and functions. Many human diseases, including cancer, have been shown to be associated with deregulated lncRNAs, rendering them potential therapeutic targets and biomarkers for differential diagnosis. The expression of lncRNAs in the nervous system varies in different cell types, implicated in mechanisms of neurons and glia, with effects on the development and functioning of the brain. Reports have also shown a link between changes in lncRNA molecules and the etiopathogenesis of brain neoplasia, including glioblastoma multiforme (GBM). GBM is an aggressive variant of brain cancer with an unfavourable prognosis and a median survival of 14–16 months. It is considered a brain-specific disease with the highly invasive malignant cells spreading throughout the neural tissue, impeding the complete resection, and leading to post-surgery recurrences, which are the prime cause of mortality. The early diagnosis of GBM could improve the treatment and extend survival, with the lncRNA profiling of biological fluids promising the detection of neoplastic changes at their initial stages and more effective therapeutic interventions. This review presents a systematic overview of GBM-associated deregulation of lncRNAs with a focus on lncRNA fingerprints in patients’ blood.

show abstract

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

Section: Emerging Lncrna Biomarkers Of Gbmmentioning

confidence: 99%

See 1 more Smart Citation

lncRNA Biomarkers of Glioblastoma Multiforme

Pokorná,

Černá,

Boussios

et al. 2024

Biomedicines

View full text Add to dashboard Cite

show abstract

“…In addition, there are some other common lncRNAs that are up-regulated in osteosarcoma. For example, the expression of BCAR4 ( 71 ), HULC ( 72 ), UCA1 ( 73 ), and ANRIL ( 74 ) in osteosarcoma tissues is significantly higher than that in osteoblasts and adjacent tissues. After knocking down BCAR4, the proliferation, invasion and migration of osteosarcoma cells were inhibited.…”

Section: Lncrnas In Osteosarcomamentioning

confidence: 99%

LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review

Hu,

Han,

Liu

et al. 2024

Front. Endocrinol.

View full text Add to dashboard Cite

Osteosarcoma is a common malignancy that often occurs in children, teenagers and young adults. Although the treatment strategy has improved, the results are still poor for most patients with metastatic or recurrent osteosarcomas. Therefore, it is necessary to identify new and effective prognostic biomarkers and therapeutic targets for diseases. Human genomes contain lncRNAs, transcripts with limited or insufficient capacity to encode proteins. They have been implicated in tumorigenesis, particularly regarding the onset, advancement, resistance to treatment, recurrence and remote dissemination of malignancies. Aberrant lncRNA expression in osteosarcomas has been reported by numerous researchers; lncRNAs have the potential to exhibit either oncogenic or tumor-suppressing behaviors and thus, to govern the advancement of this skeletal cancer. They are suspected to influence osteosarcoma cell growth, replication, invasion, migration, remote dissemination and programmed cell death. Additionally, they have been recognized as clinical markers, and may participate in the development of multidrug resistance. Therefore, the study of lncRNAs in the growth, metastasis, treatment and prognosis of osteosarcoma is very important for the active prevention and treatment of osteosarcoma. Consequently, this work reviews the functions of lncRNAs.

show abstract

Exploring the enigma: history, present, and future of long non-coding RNAs in cancer

Naseer,

Malik,

Zhang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs), which are more than 200 nucleotides in length and do not encode proteins, play crucial roles in governing gene expression at both the transcriptional and posttranscriptional levels. These molecules demonstrate specific expression patterns in various tissues and developmental stages, suggesting their involvement in numerous developmental processes and diseases, notably cancer. Despite their widespread acknowledgment and the growing enthusiasm surrounding their potential as diagnostic and prognostic biomarkers, the precise mechanisms through which lncRNAs function remain inadequately understood. A few lncRNAs have been studied in depth, providing valuable insights into their biological activities and suggesting emerging functional themes and mechanistic models. However, the extent to which the mammalian genome is transcribed into functional noncoding transcripts is still a matter of debate. This review synthesizes our current understanding of lncRNA biogenesis, their genomic contexts, and their multifaceted roles in tumorigenesis, highlighting their potential in cancer-targeted therapy. By exploring historical perspectives alongside recent breakthroughs, we aim to illuminate the diverse roles of lncRNA and reflect on the broader implications of their study for understanding genome evolution and function, as well as for advancing clinical applications.

show abstract

The Long Non-Coding RNA ANRIL in Cancers

Cited by 6 publications

References 275 publications

lncRNA Biomarkers of Glioblastoma Multiforme

lncRNA Biomarkers of Glioblastoma Multiforme

LncRNAs as potential prognosis/diagnosis markers and factors driving drug resistance of osteosarcoma, a review

Exploring the enigma: history, present, and future of long non-coding RNAs in cancer

Contact Info

Product

Resources

About